AVGO vs ZYME Stock Comparison

ZYME currently leads AVGO in this stock comparison, with AIQ scores of 68 vs 52. The clearest difference is momentum, while AVGO has the stronger quality profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 16 points
AVGO
Technology
vs
ZYME
Healthcare
AVGO
Broadcom Inc.
Price
$347
Day move
-4.76%
AIQ Score
52/100
Best edge
Quality
Sector
Technology
ZYME
Zymeworks Inc.
Leads
Price
$26.24
Day move
-0.87%
AIQ Score
68/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between AVGO and ZYME?

ZYME leads the current stock comparison as Zymeworks Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Broadcom Inc. vs Zymeworks Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Technology vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 7/10

ZYME leads

ZYME leads by 16 AIQ points, primarily on Momentum and Value, having only recently taken the lead back from AVGO.

Fragile: 6 of 6 evidence groups support ZYME, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 6 of 6Comparison trend: Reversed
AVGO

Broadcom Inc.

AIQ Score
52/100
AIQ Edge Score
7/10
ZYME

Zymeworks Inc.

Leads
AIQ Score
68/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors ZYME over AVGO, 68 versus 52 as of Nov 15, 2026. ZYME's advantage is driven primarily by stronger momentum and value, while AVGO holds the stronger quality profile. ZYME also shows the weaker technical structure relative to its 50-day moving average. 6 of 6 covered evidence groups favor ZYME today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. ZYME lead: Reversed — AVGO led by 4 AIQ points 30 sessions ago; ZYME now leads by 16.

Compare Broadcom Inc. and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

AVGO
+565.5%
ZYME
+34.0%

Total return comparison

Growth of $10,000, distributions reinvested

AVGO $66,548 · ZYME $13,401

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare AVGO and ZYME against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

AVGO advantage
0
ZYME advantage
  • Momentum40 vs 78
    ZYME +38
  • Value50 vs 66
    ZYME +16
  • Risk Resilience47 vs 61
    ZYME +14
  • Quality69 vs 62
    AVGO +7

6 of 6 evidence groups favor ZYME. ZYME’s edge is concentrated in momentum and value; AVGO keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

AVGO0 AIQ

Largest factor move: Momentum -2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 6 active signals are unchanged.

ZYME+2 AIQ

Largest factor move: Risk Resilience +4

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)

ZYME's lead widened by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — AVGO and ZYME both carry a full feed there.

The central trade-off

ZYME (Zymeworks Inc.): the stronger current systematic profile, led by momentum and value.

AVGO (Broadcom Inc.): the counter-case, on quality — but at materially higher volatility, 70% against 63.1%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ZYME

ZYME on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

AVGO

AVGO on combined revenue and EPS growth.

Value

ZYME

ZYME on the peer-relative Value factor, by 16 points.

Momentum

ZYME

ZYME on the Momentum factor, by 38 points.

Lower downside

ZYME

ZYME on Risk Resilience, by 14 points.

Analyst upside

ZYME

ZYME on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureAVGOZYMENote
Implied upside to target+48.5%+62.3%ZYME has more room
Target dispersion+48.5%+54%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering5114Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

6 of 6 covered evidence groups favor ZYME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreZYME52 vs 68
FundamentalsZYMEon balancerevenue growth 33.4% vs 54.9%; EPS growth 40.3% vs 4.9%; TTM ROE 13.1% vs 67.3%; gross margin 68.8% vs 98.3%; operating margin 48.4% vs 16.6% — ZYME takes 3 of 5 decided legs, not all of them
ValuationZYMEValue 50 vs 66
TechnicalsZYMEPrice vs 50-day 0.5% vs -4%; vs 200-day -5.6% vs 2.8%
Risk ResilienceZYMERisk Resilience 47 vs 61
Analyst expectationsZYMETarget upside 48.5% vs 62.3%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVGO and ZYME and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is wide at 16 points. (supports the conclusion holding)
  • 6 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ZYME.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ZYME lead: Reversed — AVGO led by 4 AIQ points 30 sessions ago; ZYME now leads by 16.

May 27AVGO leads above the line · ZYME leads belowNov 13
Today
ZYME +16
52 vs 68
7 sessions ago
ZYME +9
50 vs 59
30 sessions ago
AVGO +4
55 vs 51
90 sessions ago
AVGO +9
59 vs 50

The lead changed hands 2 times in this window, most recently on Oct 22 when ZYME moved ahead of AVGO.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

AVGOConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only AVGO

  • Death Cross Active — bearish, trend, long horizon (6.38%)
  • Accumulation Pattern — bullish, volume, medium horizon (1.18x)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
ZYMEConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only ZYME

  • Golden Cross Active — bullish, trend, long horizon (7.04%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon

Both carry 2 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode.

ZYME leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

AVGONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -4.76%, AIQ 0 points).

ZYMEDivergence

Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1AVGO closes the Momentum gap — currently 38 points behind, the largest single contributor to ZYME's edge.
  2. 2AVGO's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ZYME leads on balance
MetricAVGOZYME
Revenue growth (YoY)33.4%54.9%
EPS growth (YoY)40.3%4.9%
Gross margin68.8%98.3%
Operating margin48.4%16.6%
Return on equity (TTM)13.1%67.3%
Debt to equity0.62.52

Performance

Split across windows
MetricAVGOZYME
1 week (5 sessions)18.2%-11.4%
1 month (20 sessions)5.6%4.8%
3 months (63 sessions)-11.6%3.7%
6 months (126 sessions)-18.4%9.7%
Year to date0.3%-0.3%
1 year (252 sessions)-2.3%35.5%

Technicals

ZYME has the stronger structure
MetricAVGOZYME
RSI (14)53.242
ADX (14)2323.8
Price vs 50-day0.5%-4%
Price vs 200-day-5.6%2.8%
Volatility (1M, annualized)70%63.1%

Risk

ZYME is the more resilient
MetricAVGOZYME
Beta2.210.78
Sharpe ratio0.210.84
Sortino ratio0.291.39
Max drawdown-39.5%-23.6%
Current drawdown-27.9%-16.6%
Annualized volatility48.6%54%
Value at risk (95%)-4.6%-4.1%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, AVGO or ZYME?

On the Algovestiq AIQ Score, ZYME is the stronger of the two as of Nov 15, 2026, scoring 68 against AVGO's 52. The edge comes from momentum and value. AVGO is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is AVGO or ZYME the better buy right now?

ZYME carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 6 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.

Why does the AIQ Score favor ZYME over AVGO?

The composite weights Quality, Value, Momentum and Risk Resilience. ZYME leads Momentum by 38 points; ZYME leads Value by 16 points; ZYME leads Risk Resilience by 14 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, AVGO or ZYME?

Analyst price targets imply +48.5% upside for AVGO and +62.3% for ZYME, so the Street currently favors ZYME. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, AVGO or ZYME?

ZYME is the better-valued of the two on the peer-relative Value factor. ZYME on the peer-relative Value factor, by 16 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, AVGO or ZYME?

AVGO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, AVGO or ZYME?

ZYME on the Momentum factor, by 38 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, AVGO or ZYME?

ZYME is the more resilient of the two, so the other name carries the higher downside risk. ZYME on Risk Resilience, by 14 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is AVGO more profitable than ZYME?

The profitability evidence is mixed: gross margin 68.8% vs 98.3%; operating margin 48.4% vs 16.6%; ttm roe 13.1% vs 67.3%. AVGO leads on one measure and ZYME on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is ZYME's lead over AVGO getting stronger or weaker?

ZYME lead: Reversed — AVGO led by 4 AIQ points 30 sessions ago; ZYME now leads by 16. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-10-22, when ZYME moved ahead of AVGO.

What would change the AVGO vs ZYME verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AVGO closes the Momentum gap — currently 38 points behind, the largest single contributor to ZYME's edge; AVGO's Death Cross Active resolves — a bearish trend rule currently active against it; ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about AVGO and ZYME?

AVGO: 2 bullish / 2 bearish / 2 neutral, conflicted. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Death Cross Active (bearish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).

Compare AVGO and ZYME with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.